title: Tumor volume or dynamic contrast-enhanced MRI for prediction of clinical outcome of Ewing sarcoma family of tumors.
abstract: BACKGROUND
  The identification of risk factors that predict poor clinical outcome at the time of diagnosis could lead to intensified early therapy and improved outcome for pediatric patients with Ewing sarcoma family of tumors (ESFT).
  
  
  OBJECTIVE
  To compare the effectiveness of static magnetic resonance (MR) imaging measurements of tumor volume with variables obtained by dynamic contrast-enhanced MR imaging (DEMRI) in predicting ESFT outcome.
  
  
  METHODS
  MR examinations that included DEMRI were retrospectively reviewed. The analyses included 45 examinations of 21 patients with ESFT (performed from 1992 to 1996). Tumor volumes were measured on the static MR images, and the regions of interest were selected for DEMRI analysis. The relationships of static MR imaging and DEMRI variables with the probability of progression-free survival (PFS) and disease-free survival (DFS) were determined.
  
  
  RESULTS
  Larger tumor volume at the time of diagnosis predicted poorer PFS and DFS estimates. No DEMRI variable predicted outcome.
  
  
  CONCLUSIONS
  Determination of tumor volume by static MR imaging at the time of diagnosis is a simple and reliable method of predicting the clinical outcome of patients with ESFT. DEMRI is not as reliable a technique as static MR imaging for predicting the outcome of these patients.
authors.affiliation: Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis TN 38105-2794, USA.
authors.forename: S L
authors.initials: SL
authors.lastname: Miller
authors.forename: F A
authors.initials: FA
authors.lastname: Hoffer
authors.forename: W E
authors.initials: WE
authors.lastname: Reddick
authors.forename: S
authors.initials: S
authors.lastname: Wu
authors.forename: J O
authors.initials: JO
authors.lastname: Glass
authors.forename: S A
authors.initials: SA
authors.lastname: Gronemeyer
authors.forename: M
authors.initials: M
authors.lastname: Haliloglu
authors.forename: A Y
authors.initials: AY
authors.lastname: Nikanorov
authors.forename: X
authors.initials: X
authors.lastname: Xiong
authors.forename: A S
authors.initials: AS
authors.lastname: Pappo
mesh_terms: D000293:Adolescent; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000473:pathology*; D002648:Child; D002675:Child, Preschool; D003287:Contrast Media; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012044:Regression Analysis; D012189:Retrospective Studies; D012512:Sarcoma, Ewing / Q000188:drug therapy / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003287:Contrast Media; D003520:Cyclophosphamide